Illumina, Inc. (ILMN) Deep Dive Video

Summary

Post-GRAIL, Illumina is refocusing on NovaSeq X and clinical consumables—using multiomics and AI to defend its sequencing moat amid China and competition headwinds.

View ILMN stock page · Read the ILMN research report

Loading the video player…